Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carc
3 hours ago
- #Multimodal therapy
- #Predictive model
- #Hepatocellular carcinoma
- A multimodal therapeutic efficacy model was developed to predict early treatment response in unresectable hepatocellular carcinoma (uHCC) patients undergoing TACE-HAIC combined with ICIs and TKIs.
- The study included 205 uHCC patients from two institutions, analyzing enhanced CT imaging features, DSA characteristics, and clinical parameters to build the predictive model.
- The combined model demonstrated strong predictive performance with AUCs of 0.944 (training cohort), 0.916 (internal validation), and 0.902 (external validation).
- The model integrates hepatic DSA, CT imaging, and clinical data, showing excellent calibration and clinical utility for optimizing treatment strategies.
- Key findings highlight the importance of accurate early response prediction to avoid unnecessary toxicity and economic burden in non-responsive patients.